These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 1465795)

  • 1. Collaborative Transplant Study--10-year report.
    Opelz G
    Transplant Proc; 1992 Dec; 24(6):2342-55. PubMed ID: 1465795
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of HLA-DR matching on rejection after cardiac transplantation.
    Cochrane A; Benson E; Williams T; Bergin P; Esmore D
    Transplant Proc; 1992 Feb; 24(1):169-70. PubMed ID: 1539227
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
    Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
    Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunological advances in clinical transplantation.
    Morris PJ
    Transplant Proc; 1992 Dec; 24(6):2356-8. PubMed ID: 1465796
    [No Abstract]   [Full Text] [Related]  

  • 5. Five-year experience with a triple drug protocol in renal transplantation.
    Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
    Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
    [No Abstract]   [Full Text] [Related]  

  • 6. Value of monoclonal antibody OKT3 in solid organ transplantation: a meta-analysis.
    Carrier M; Jenicek M; Pelletier LC
    Transplant Proc; 1992 Dec; 24(6):2586-91. PubMed ID: 1465874
    [No Abstract]   [Full Text] [Related]  

  • 7. Quality of serological donor HLA typing: analysis of graft survival by HLA in renal transplantation recipients treated with cyclosporine.
    Thorogood J; Schreuder GM; Persijn GG; van Rood JJ
    Transplant Proc; 1992 Dec; 24(6):2485-7. PubMed ID: 1465839
    [No Abstract]   [Full Text] [Related]  

  • 8. Six-year experience with a triple drug protocol in renal transplantation: analysis of risk factors.
    Pallardó LM; Sánchez P; Sánchez J; García J; Orero E; Beneyto I; Cruz JM
    Transplant Proc; 1992 Dec; 24(6):2714-5. PubMed ID: 1465911
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
    Chen M; Wade J; Levy GA; Greig PD
    Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimization of cyclosporine monotherapy--long-term graft function.
    Birkeland SA; Elbirk A; Rohr N; Jørgensen KA
    Transplant Proc; 1994 Oct; 26(5):2501-6. PubMed ID: 7940767
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuncts to triple-drug therapy after cardiac transplantation: a comparison of Nashville rabbit antithymocyte serum to OKT3.
    Aziz S; Kruse AP; Roby PV; Allen MD; Khan K; Fishbein D
    Transplant Proc; 1994 Oct; 26(5):2721-3. PubMed ID: 7940852
    [No Abstract]   [Full Text] [Related]  

  • 12. Late acute rejection in renal transplant recipients: response to steroid treatment.
    Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
    Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
    [No Abstract]   [Full Text] [Related]  

  • 13. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokine-release syndrome: differences between high and low doses of OKT3.
    Norman DJ; Kimball JA; Barry JM
    Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
    [No Abstract]   [Full Text] [Related]  

  • 15. Triple drug maintenance therapy in renal transplantation.
    Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
    Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhanced renal graft survival in HLA-A mismatched transplants.
    Bućin D; Ekberg H; Lindholm A; Persson H; Tufvesson G; Albrechtsen D
    Transplant Proc; 1992 Dec; 24(6):2473-4. PubMed ID: 1465837
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of HLA antigens of renal transplant recipients on graft survival.
    Alamartine E; Berthoux F; Acquart S; Lepetit JC
    Transplant Proc; 1992 Dec; 24(6):2461-2. PubMed ID: 1465831
    [No Abstract]   [Full Text] [Related]  

  • 18. Strategy for improving retransplantation in the CyA era.
    Dickerman R; Langley J; Brinker K; Trevino G; Melton L; Vergne-Marini P; Wilson PK
    Transplant Proc; 1993 Feb; 25(1 Pt 1):257-8. PubMed ID: 8438292
    [No Abstract]   [Full Text] [Related]  

  • 19. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
    Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
    Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
    [No Abstract]   [Full Text] [Related]  

  • 20. Special issues related to transplantation in Japan.
    Amemiya H; Sada M; Ichikawa Y; Fukuda Y
    Transplant Proc; 1992 Dec; 24(6):2428-9. PubMed ID: 1465817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.